BUPARLISIB
Total Payments
$2.1M
Transactions
236
Doctors
61
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $54,635 | 4 | 0 |
| 2019 | $129,729 | 75 | 59 |
| 2018 | $436,235 | 38 | 0 |
| 2017 | $1.5M | 119 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.0M | 169 | 97.6% |
| Consulting Fee | $43,025 | 9 | 2.1% |
| Food and Beverage | $7,062 | 58 | 0.3% |
Payments by Type
Research
$2.0M
169 transactions
General
$50,087
67 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE III RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF BKM120 WITH FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHICH PROGRESSED ON OR AFTER AROMATASE INHIBITOR TREATMENT | Novartis Pharmaceuticals Corporation | $407,362 | 0 |
| PHASE I CLINICAL TRIAL OF BUPARLISIB AND IBRUTINIB IN MANTLE CELL LYMPHOMA FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B CELL LYMPHOMA | Novartis Pharmaceuticals Corporation | $381,403 | 0 |
| A PHASE I STUDY OF BKM120 AND EVEROLIMUS IN ADVANCED SOLID MALIGNANCIES | Novartis Pharmaceuticals Corporation | $185,920 | 0 |
| PHASE II STUDY OF BKM120 PLUS CAPECITABINE FOR TRIPLE NEGATIVE BREAST CANCER TNBC PATIENTS WITH BRAIN METASTASES | Novartis Pharmaceuticals Corporation | $147,226 | 0 |
| MODULAR PHASE II STUDY TO LINK TARGETED THERAPY TO PATIENTS WITH PATHWAY ACTIVATED TUMORS MODULE 1 BKM120 FOR PATIENTS WITH PI3K ACTIVATED TUMORS | Novartis Pharmaceuticals Corporation | $138,552 | 0 |
| PHASE I DOSE ESCALATION STUDY OF BKM120 AND CAPECITABINE IN PATIENTS WITH METASTATIC BREAST CANCER | Novartis Pharmaceuticals Corporation | $134,124 | 0 |
| A PHASE III RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF BKM120 WITH FULVESTRANTIN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE AI TREATED LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO PORGRESSED ON OR AFTER MTOR INHIBITOR BASED TREATMENT | Novartis Pharmaceuticals Corporation | $118,950 | 0 |
| A PHASE IB STUDY OF BMK120 WITH WEEKLY CISPLATIN AND RADIOTHERAPY IN HIGH RISK LOCALLY ADVANCED SQUAMOUS CELL CANCER OF THE HEAD AND NECK | Novartis Pharmaceuticals Corporation | $107,290 | 0 |
| PHASE II CLINICAL TRIAL OF BKM120 IN RECURRENT THYMOMA | Novartis Pharmaceuticals Corporation | $63,137 | 0 |
| PHASE I AND OR II STUDY OF THE ORAL PI3KINASE INHIBITOR BKM120 AND THE ORAL PARP INHIBITOR OLAPARIB IN PATIENTS WITH RECURRENT TRIPLE NEGATIVE BREAST CANCER AND THOSE WITH HIGH GRADE SEROUS OVARIAN CANCER WITH AND WITHOUT A KNOWN GERMLINE BRCA 1 OR 2 MUTATION | Novartis Pharmaceuticals Corporation | $51,261 | 0 |
| PHASE I AND OR II STUDY OF THE ORAL PI3KINASE INHIBITOR BKM120 AND THE ORAL PARP INHIBITOR OLAPARIB IN PATIENTS WITH RECURRENT TRIPLE NEGATIVE BREAST CANCER AND THOSE WITH HIGH GRADE SEROUS OVARIAN CANCER WITH AND WITHOUT A KNOWN GERMLINE BRCA 1 OR 2 MUTA | Novartis Pharmaceuticals Corporation | $38,326 | 0 |
| PHASE II MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY ASSESSING THE EFFICACY OF BUPARLISIB BKM120 PLUS PACLITAXEL VS PLACEBO PLUS PACLITAXEL IN PATIENTS WITH PLATINUM PRE TREATED RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA | Novartis Pharmaceuticals Corporation | $33,985 | 0 |
| PHASE I AND OR II STUDY OF THE COMBINATION OF BKM 120 AND BEVACIZUMAB IN PATIENTS WITH REFRACTORY SOLID TUMORS PHASE I AND RELAPSED AND OR REFRACTORY GLIOBLASTOMA MULTIFORME PHASE II | Novartis Pharmaceuticals Corporation | $30,720 | 0 |
| PHASE II STUDY OF BKM120 FOR RECURRENT GLIOBLASTOMA | Novartis Pharmaceuticals Corporation | $28,900 | 0 |
| A PHASE I STUDY OF BKM120 AND RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B CELL NON HODGKINS LYMPHOMA AND MANTLE CELL LYMPHOMA | Novartis Pharmaceuticals Corporation | $26,150 | 0 |
| A PHASE II STUDY OF BKM120 IN PATIENTS WITH RELAPSE AND REFRACTORY MANTLE CELL LYMPHOMA FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B CELL LYMPHOMA | Novartis Pharmaceuticals Corporation | $20,392 | 0 |
| AN OPEN LABEL MULTICENTER PHASE IB STUDY OF ORALLY ADMINISTERED BKM120 IN COMBINATION WITH TEMOZOLOMIDE IN PATIENTS WITH GLIOBASTOMA MULTIFORME AND ACTIVATE PI3K PATHWAY | Novartis Pharmaceuticals Corporation | $19,489 | 0 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE II STUDY OF BKM120 PLUS PACLITAXEL IN PATIENTS WITH HER2 NEGATIVE INOPERABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH OR WITHOUT PI3K PATHWAY ACTIVATION | Novartis Pharmaceuticals Corporation | $18,675 | 0 |
| A PHASE IB AND OR II STUDY OF CARBOPLATIN AND PACLITAXEL WITH OR WITHOUT BUPARLISIB IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC NON SMALL CELL LUNG CANCER NSCLC OF SQUAMOUS HISTOLOGY | Novartis Pharmaceuticals Corporation | $15,018 | 0 |
| A PHASE II TRIAL OF BKM120 IN RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND RECURRENT SECONDARY CNS LYMPHOMA PATIENTS | Novartis Pharmaceuticals Corporation | $12,409 | 0 |
Top Doctors Receiving Payments for BUPARLISIB — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Ophthalmology | Fort Wayne, IN | $121.75 | 1 |
| , M.D | Ophthalmology | Liverpool, NY | $121.75 | 1 |
| , M.D | Ophthalmology | Cincinnati, OH | $121.75 | 1 |
| , M.D | Specialist | Shawnee Mission, KS | $121.75 | 1 |
| , M.D | Ophthalmology | Spokane, WA | $121.75 | 1 |
| , MD | Retina Specialist | Rancho Cordova, CA | $121.75 | 1 |
| , MD | Ophthalmology | Winston Salem, NC | $121.75 | 1 |
| , MD | Ophthalmology | Palm Beach Gardens, FL | $121.75 | 1 |
| Jared Nielsen | — | West Des Moines, IA | $121.75 | 1 |
| , M.D | Ophthalmology | Ventura, CA | $121.75 | 1 |
| , MD | Ophthalmology | Ventura, CA | $121.75 | 1 |
| , MD | Retina Specialist | Southern Pines, NC | $121.75 | 1 |
| , MD | Retina Specialist | Oakland, CA | $121.75 | 1 |
| , MD | Ophthalmology | Mount Dora, FL | $121.75 | 1 |
| , M.D., PH.D | Ophthalmology | Riverside, CA | $121.75 | 1 |
| , M.D | Ophthalmology | Pompano Beach, FL | $121.75 | 1 |
| , M.D | Ophthalmology | Los Angeles, CA | $121.75 | 1 |
| , MD | Retina Specialist | Abilene, TX | $121.75 | 1 |
| , MD | Retina Specialist | Saint Louis, MO | $121.75 | 1 |
| , MD | Ophthalmology | Traverse City, MI | $121.75 | 1 |
| , MD | Ophthalmology | Edmond, OK | $121.75 | 1 |
| , M.D., M.P.H | Ophthalmology | Madison, WI | $121.75 | 1 |
| , MD | Ophthalmology | Madison, WI | $121.75 | 1 |
| , MD, PHD | Ophthalmology | Abilene, TX | $121.75 | 1 |
| Gregg Kokame | Ophthalmology | Aiea, HI | $121.75 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.1M
- Total Doctors 61
- Transactions 236
About BUPARLISIB
BUPARLISIB is a drug associated with $2.1M in payments to 61 healthcare providers, recorded across 236 transactions in the CMS Open Payments database. The primary manufacturer is NOVARTIS PHARMACEUTICALS CORPORATION.
Payment data is available from 2017 to 2020. In 2020, $54,635 was paid across 4 transactions to 0 doctors.
The most common payment nature for BUPARLISIB is "Unspecified" ($2.0M, 97.6% of total).
BUPARLISIB is associated with 20 research studies, including "A PHASE III RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF BKM120 WITH FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHICH PROGRESSED ON OR AFTER AROMATASE INHIBITOR TREATMENT" ($407,362).